



Timpson, N. J. (2020). Diving deep—multipronged investigations into RIPK1 as a risk factor for obesity. *Nature Metabolism*, 2, 997–998 (2020). <https://doi.org/10.1038/s42255-020-00284-5>

Peer reviewed version

Link to published version (if available):
[10.1038/s42255-020-00284-5](https://doi.org/10.1038/s42255-020-00284-5)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Nature Research at <https://doi.org/10.1038/s42255-020-00284-5> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Diving deep – multi-pronged investigations into *RIPK1* as risk factor for obesity.

Nicholas John Timpson^{1,2}

¹MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, BS8 2BN, UK

²Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, BS8 2BN, UK

A recent study by Karunakaran et al. has suggested RIPK1 is important in obesity and related metabolic traits. With genetic variation associated with expression and the risk of obesity, and repression of activity leading to a favorable metabolic profile in an obesogenic model, is there evidence for a potential therapeutic role?

Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a regulator of autoinflammatory systems and appears intimately involved in the coordination of events around cell death. There is a body of evidence which marks out RIPK1 as an important regulator for inflammatory events in both normative settings and disease. RIPK1 is able to play a role in the triggering of cell death, but it also can act to regulate inflammatory signaling and promote cell survival¹. Indeed, in atherosclerosis, it has been suggested that pathways involved in necrosis are triggered and that this can predispose weakness in plaques/lesions². This flags such regulators for therapeutic interventions and RIPK1 has received recent attention. RIPK1 is not only a potential route to the modulation of key biological systems important in common complex disease¹, but it is also an exciting and tractable target². This is because of the kinase structure of RIPK1 being an excellent target for the development of potentially effective specific pharmacological small-molecule inhibitors.

The present work ([*ref](#)) suggests that genetic variation at the *RIPK1* locus (or nearby) is associated with expression of the coded protein and that these events are also associated with the risk of obesity in human. Whilst the finding of an association between cis variation and expression is not entirely surprising, the authors are also able to show that one of the associated single nucleotide polymorphisms is within a transcription factor binding site associated with promoter activity and *RIPK1* gene expression in adipose. This is then further advanced by the observed effects of therapeutic silencing in a model of diet induced obesity - associated with fat mass, total body weight, improved insulin sensitivity, reduced macrophage count and promoted invariant natural killer T-cell accumulation. These events, which are of course subject to the limitations of system level interpretation are fascinating and more-so flag the importance of multi-pronged assessment of likely biological function. This type of evidence triangulation has been promoted in other fields^{3,4} and is the hallmark of exceptional science looking to start breaking down biological complexities into real understanding. In this new work on *RIPK1*, there is a refreshing combination of human genetic epidemiology, model and cell work which builds on the story of this gene and the potential role it has in a range of important biological processes (**Figure 1**).

More generally, this paper forms part of a growing collection of studies looking to use genetic variation to increase the functional understanding of underlying biological events. It is increasingly clear that there is breadth in the shape of genetic contributions to disease⁵ and whilst the associations with outcomes and intermediate traits are reliable, the architecture of these genetic contributions varies wildly. That said, it is clear that the differing types of genetic association study are useful and capable of yielding insight into pathways of interest. What is less clear, however, is how one navigates the difficult path of moving from signal to biological understanding.

This tricky road has been walked by papers which really have started to use sensible collections of existing resources to unpick the deeper stories behind association results. For example, the strong association between genetic variation at *FTO* on chromosome 16 and adiposity uncovered in part through its logical relationship with type 2 diabetes^{6,7} has been well cross-examined and by those able to deploy existing collections of deep genomic data to explore why and how the association might exist⁸. Indeed, some of the earliest association signals for adiposity coming first from familial studies of extreme phenotype are now being explored with both a view to the existence of common and well explored rare genetic variation⁹. Despite these advances, the bridge between reliable signal and function – which theoretically can lead to an ability to consider possible therapeutic value – is one which remains extremely difficult to cross, but is the paradigm of the work discussed here.

Finding genetic variation at, or around *RIPK1* (some of which looks to be regulatory) which is associated with expression in the appropriate tissue and which is associated with a risk of elevated adiposity is compelling. The combination of this with analysis of therapeutically knocked down expression in an overweight model and the observation of the right “milieu” of biological events (inflammatory, immunological, body composition and glycemic profile) is exciting and brings a clear addition to an existing literature. However, one is constantly reminded that there are rarely enough tools to fully assess a complex regulatory network such as that involving RIPK1. The suppression of a key regulator seems likely to inevitably yield systemic changes and the qualification of specific genetic variants as useful proxies/handles for understanding the impact of RIPK1 on obesity leaves a cautionary feel to the new work. Furthermore, with inflammation and body composition in particular, one enters the murky waters of reverse causation and likely bidirectional effects, which would require careful examination before embarking on work setting out to measure clinical effectiveness.

This work clearly has not refuted the likely importance of RIPK1 and at worst has marked it as a sentinel or reporter for a network of regulatory events which are coincident in a number of complex diseases. Evidence presented by Karunakaran and colleagues furthers the hypothesis that there is likely to be a meaningful biological read out of specific therapeutic manipulation of RIPK1 (even if subject to the complexities and redundancies of the systems targeted). Furthermore, the work has delivered a multi-pronged attack on trying to understand the potential role of RIPK1 across cell, model and human investigation. There is potential in this attractive target to deliver increased metabolic control in the context of a prevailing obesogenic environment and population level obesity control aside, this parallel development is a tantalizing prospect.

The author declare no competing interests.

NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169).

References:

1. Mifflin, L., Ofengeim, D. & Yuan, J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. *Nat. Rev. Drug Discov.* **19**, 553–571 (2020).
2. Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. *Proc. Natl. Acad. Sci.* **116**, 9714 LP – 9722 (2019).
3. Munafo, M. R. & Davey-Smith, G. Verifying results requires disparate lines of evidence — a technique called triangulation. *Nature* **553**, 399–401 (2018).
4. Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology. *Int. J. Epidemiol.* **45**, dyw314 (2017).
5. Timpson, N. J., Greenwood, C. M. T., Soranzo, N., Lawson, D. J. & Richards, J. B. Genetic architecture: the shape of the genetic contribution to human traits and disease. *Nat. Rev. Genet.* **19**, 110 (2018).
6. Wellcome Trust Case Control Consortium. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. *Nature* **447**, 661–678 (2007).
7. Frayling, T. M. *et al.* A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity. *Science* (80). **316**, 889–894 (2007).
8. Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. *N. Engl. J. Med.* **373**, 895–907 (2015).
9. Lotta, L. A. *et al.* Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity. *Cell* **177**, 597-607.e9 (2019).
10. Laakso, M. *et al.* The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. *J. Lipid Res.* **58**, 481–493 (2017).

11. Davies, R. W. *et al.* A 680 kb duplication at the FTO locus in a kindred with obesity and a distinct body fat distribution. *Eur. J. Hum. Genet.* **21**, 1417–1422 (2013).

Figure 1. Triangulation of evidence around RIPK1 as a candidate for a role in body composition related cellular pathways.

Schematic representing multiple independent sources of evidence highlighting the likely importance of RIPK1. **A** – human studies relating genetic variation at *RIPK1* associated with expression, risk of obesity and suggesting a causal role for RIPK1 in adiposity, **B** – murine studies suggesting that the specific repression of RIPK1 expression affects a suite of metabolic traits in a diet induced model of obesity. **C** – evidence that genetic variation relating to human studies resides in a transcription factor binding site for E4BP4 and influences RIPK1 promotion. Green arrows indicate evidence from Karunakaran *et al.* and from different sources supporting important roles for RIPK1 in obesity and metabolic traits. Red arrows are indicative of important followup work which can be prompted by that reported by Karunakaran *et al.* ASO refers to Anti-sense oligonucleotide, MR refers to Mendelian randomisation and eQTL refers to expression quantitative trait locus. METSIM¹ gives reference to Metabolic Syndrome in Men Study which was used to examine the relationship between genetic variation at RIPK1 and RIPK1 mRNA (eQTL discovery)¹⁰. OTTAWA² refers to a cohort of participants recruited for the study of genetic variation at the FTO locus, but used by Karunakaran and colleagues for the analysis of genetic association between RIPK1 variation and the risk of obesity¹¹.


A

METSIM¹
eQTL → mRNA


OTTAWA²
↑ risk obesity

eQTL MR → obesity
Multiple cohorts

AAGGTCCA(A/G)ATCCAAA

**B**

Further followup - Murine expression studies



ASO




**Triangulation of
evidence**

Further followup - Human expression studies

C

AAGGTCCA(A/G)ATCCAAA

**TFBS
(E4BP4)**



Further followup - ASO direction and cell function